Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Inventory (2016 - 2026)

Heron Therapeutics filings provide 11 years of Inventory readings, the most recent being $92.5 million for Q1 2026.

  • On a quarterly basis, Inventory rose 62.54% to $92.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $92.5 million, a 62.54% increase, with the full-year FY2025 number at $92.7 million, up 74.47% from a year prior.
  • Inventory hit $92.5 million in Q1 2026 for Heron Therapeutics, roughly flat from $92.7 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $92.7 million in Q4 2025 to a low of $100000.0 in Q1 2024.
  • Median Inventory over the past 5 years was $53.2 million (2024), compared with a mean of $54.9 million.
  • Biggest five-year swings in Inventory: plummeted 99.81% in 2024 and later skyrocketed 56832.0% in 2025.
  • Heron Therapeutics' Inventory stood at $54.6 million in 2022, then decreased by 22.84% to $42.1 million in 2023, then increased by 26.24% to $53.2 million in 2024, then skyrocketed by 74.47% to $92.7 million in 2025, then decreased by 0.22% to $92.5 million in 2026.
  • The last three reported values for Inventory were $92.5 million (Q1 2026), $92.7 million (Q4 2025), and $70.0 million (Q3 2025) per Business Quant data.